AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Super League Enterprise, Inc.
Video analysis: SLE
All videosNo video analysis for this stock yet. Request one from our team.
News: SLE
Metaplanet to Invest 2,100 Bitcoin in Super League to Launch U.S. Bitcoin Treasury Platform, Superplanet
Super League to be renamed “Superplanet, Inc.” and become Metaplanet's U.S. Bitcoin treasury platform, backed by the world's third-largest corporate Bitcoin holder with 43,000 BTC
Super League Enterprise, Inc. (SLE) Q2 2026 Earnings Call Transcript
Super League Enterprise, Inc. (SLE) Q2 2026 Earnings Call Transcript
Super League Reports Second Quarter 2026 Financial Results, Highlighted by Improving Margins and Operating Performance
Net Revenue increases 16% sequentially as gross margin expands five percentage points to 41% Adjusted EBITDA improves approximately 20% year-over-year as Company maintains disciplined cost structure SANTA MONICA, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE) (the “Company”), an audience intelligence and media activation company trusted by global brands to reach and engage people who play video games across the digital advertising landscape, today announced financial results for the second quarter ended June 30, 2026, reflecting continued operating progress despite a challenging advertising environment.
Super League Sets Second Quarter 2026 Earnings Date, August 14, 2026
SANTA MONICA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE) (the “Company”), an audience intelligence and media activation company trusted by global brands to reach and influence people who play video games across the digital landscape, announced today that the Company will post its second quarter 2026 financial results before market open on Friday, August 14, 2026. A webinar will be held the same day at 8:30 am Eastern Time to discuss the results and can be accessed using the below dial-in numbers or registration link.
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNISÂ
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained dise
